Comparative Pharmacology
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHAZINE W DEXTROMETHORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHAZINE W DEXTROMETHORPHAN.
NEOTRIZINE vs PROMETHAZINE W/ DEXTROMETHORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neotrizine contains sulfadiazine, a competitive inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
NEOTRIZINE (sulfamethoxazole/trimethoprim) 800 mg/160 mg orally every 12 hours for 5-14 days, depending on indication.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; in renal impairment, half-life may extend to 12-18 hours requiring dose adjustment.
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal elimination accounts for 20-30%, with the remainder as metabolites.
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic